Renaissance Technologies (RenTech)'s AKBA Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 3.59 M shares of Akebia Therapeutics, Inc. (AKBA) worth $5.78 M, representing 0.01% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in AKBA, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2023, adding 1.62 M shares. Largest reduction occurred in Q4 2018, reducing 1.78 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Akebia Therapeutics (AKBA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Akebia Therapeutics (AKBA) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -359,594 | Reduce 9.10% | 3.59 M | $1.61 |
| Q3 2025 | -241,700 | Reduce 5.76% | 3.95 M | $2.73 |
| Q2 2025 | +188,600 | Add 4.71% | 4.19 M | $3.64 |
| Q1 2025 | +182,300 | Add 4.77% | 4.01 M | $1.92 |
| Q4 2024 | +105,727 | Add 2.84% | 3.82 M | $1.90 |
| Q3 2024 | -197,000 | Reduce 5.03% | 3.72 M | $1.32 |
| Q2 2024 | +262,700 | Add 7.19% | 3.91 M | $1.02 |
| Q1 2024 | -1.13 M | Reduce 23.59% | 3.65 M | $1.83 |
| Q4 2023 | +1.62 M | Add 51.47% | 4.78 M | $1.24 |
| Q3 2023 | -175,300 | Reduce 5.26% | 3.16 M | $1.14 |
| Q2 2023 | +992,227 | Add 42.43% | 3.33 M | $0.00 |
| Q1 2023 | -547,727 | Reduce 18.98% | 2.34 M | $0.00 |
| Q4 2022 | -130,200 | Reduce 4.32% | 2.89 M | $0.00 |
| Q3 2022 | +1.53 M | Add 103.50% | 3.02 M | $0.32 |
| Q2 2022 | +478,973 | Add 47.74% | 1.48 M | $0.35 |
| Q1 2022 | +380,300 | Add 61.04% | 1 M | $0.72 |
| Q4 2021 | -326,900 | Reduce 34.41% | 623,027 | $2.26 |
| Q3 2021 | -877,803 | Reduce 48.03% | 949,927 | $2.88 |
| Q2 2021 | +757,149 | Add 70.72% | 1.83 M | $3.79 |
| Q1 2021 | -377,346 | Reduce 26.06% | 1.07 M | $3.39 |
| Q4 2020 | +1.38 M | Add 1963.31% | 1.45 M | $2.80 |
| Q3 2020 | -5,514 | Reduce 7.29% | 70,175 | $2.51 |
| Q2 2020 | +75,689 | New Buy | 75,689 | $13.58 |
| Q1 2020 | -138,527 | Sold Out | 0 | $0.00 |
| Q4 2019 | +95,100 | Add 218.99% | 138,527 | $6.32 |
| Q3 2019 | +43,427 | New Buy | 43,427 | $3.91 |
| Q4 2018 | -1.78 M | Sold Out | 0 | $0.00 |
| Q3 2018 | -97,629 | Reduce 5.21% | 1.78 M | $8.83 |
| Q2 2018 | -644,500 | Reduce 25.58% | 1.87 M | $9.98 |
| Q1 2018 | +697,900 | Add 38.32% | 2.52 M | $9.53 |
| Q4 2017 | +400,300 | Add 28.17% | 1.82 M | $14.87 |
| Q3 2017 | +395,600 | Add 38.58% | 1.42 M | $19.67 |
| Q2 2017 | +639,033 | Add 165.44% | 1.03 M | $14.37 |
| Q1 2017 | +177,667 | Add 85.17% | 386,267 | $9.20 |
| Q4 2016 | +56,800 | Add 37.42% | 208,600 | $10.41 |
| Q3 2016 | +127,500 | Add 524.69% | 151,800 | $9.05 |
| Q2 2016 | -4,200 | Reduce 14.74% | 24,300 | $7.49 |
| Q1 2016 | -80,700 | Reduce 73.90% | 28,500 | $9.02 |
| Q4 2015 | -1,500 | Reduce 1.36% | 109,200 | $12.92 |
| Q3 2015 | -270,539 | Reduce 70.96% | 110,700 | $9.66 |
| Q2 2015 | +381,239 | New Buy | 381,239 | $10.29 |
Renaissance Technologies (RenTech)'s Akebia Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Akebia Therapeutics, Inc. (AKBA) in Q2 2015, acquiring 381,239 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Akebia Therapeutics, Inc. (AKBA) for 41 quarters since Q2 2015.
Renaissance Technologies (RenTech)'s largest addition to Akebia Therapeutics, Inc. (AKBA) was in Q4 2023, adding 4,779,383 shares worth $5.93 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 3,593,133 shares of Akebia Therapeutics, Inc. (AKBA), valued at approximately $5.78 M.
As of the Q4 2025 filing, Akebia Therapeutics, Inc. (AKBA) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Akebia Therapeutics, Inc. (AKBA) was 4,779,383 shares, as reported at the end of Q4 2023.